Meta-analysis of 4 studies (3 RCTs, 1 real-world; 1199 patients) in relapsed/refractory large B-cell lymphoma: second-line CAR-T improved OS (HR 0.75), EFS (HR 0.51) and PFS (HR 0.47) vs standard care; hypogammaglobulinaemia was more frequent with CAR-T.
Meta-analysisn = 1,199
Tang et al. Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis